Long-term outcome of urea cycle disorders
1Laboratoire Central de Chimie Clinique, Université de Lausanne, CHUV, Switzerland. Claude.Bachmann@chuv.ch
Acta Gastro-Enterologica Belgica
|January 26, 2006
Summary
Modern treatment for urea cycle diseases (UCD) improves survival but may increase intellectual disability. Prognosis depends on ammonia levels and coma duration, with dietary management crucial for better outcomes.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Urea cycle diseases (UCD) are rare inherited metabolic disorders.
- Long-term outcome data for UCD patients are essential for clinical management and genetic counseling.
- Current treatment strategies aim to reduce ammonia levels and prevent hyperammonemic crises.
Purpose of the Study:
- To evaluate the long-term outcomes of patients with urea cycle diseases under different treatment regimens.
- To identify prognostic factors for neurological handicap in UCD patients.
- To assess the impact of modern conservative treatment versus historical protein restriction-only diets.
Main Methods:
- Comparative analysis of patient outcomes based on historical (protein restriction) and modern (conservative) treatment protocols.
- Discussion of potential biases in long-term studies of rare genetic disorders.
- Evaluation of prognostic criteria including peak ammonia levels and coma duration.
Main Results:
- Modern conservative treatment for UCD improves patient survival rates compared to historical methods.
- Improved survival is associated with a higher incidence of intellectual disability among surviving patients.
- Inadequate dietary compensation for branched-chain amino acid deficiency, exacerbated by phenylbutyrate, may contribute to suboptimal outcomes.
Conclusions:
- Enhanced survival in UCD patients treated with modern conservative methods comes at the cost of increased intellectual disability.
- Peak ammonia levels and coma duration are proposed as key prognostic indicators for neurological handicap.
- Optimizing dietary management, particularly branched-chain amino acid supplementation, is critical for improving long-term results in UCD, especially as a bridge to liver transplantation.
Related Concept Videos
01:23Urea Cycle
The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:15Drug Elimination by Renal Route: Tubular Secretion
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
01:29Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...